The Role and Efficacy of Coenzyme Q10 in the Management of Erectile Dysfunction in a Hypertensive Male: An Interventional Study

Victor H Aguilera-Alvarez; Bilal Khan Mohammed; Aqsa Fatima; Ankit Patel; Avaniben Patel; Frederick N Gyabaah; Jobby John; Abbas Iqbal; Sidra Naz; Affan Munir; Ammer Haffar; Muhammad Irfan; Muhammad Hanif

doi:10.7759/cureus.17937

The Role and Efficacy of Coenzyme Q10 in the Management of Erectile Dysfunction in a Hypertensive Male: An Interventional Study

Cureus. 2021 Sep 13;13(9):e17937. doi: 10.7759/cureus.17937. eCollection 2021 Sep.

Authors

Affiliations

¹ Health Policy, Imperial College London, London, GBR.
² Internal Medicine, Deccan College of Medical Sciences, Hyderabad, IND.
³ Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.
⁴ Internal Medicine, Spartan Health Science University School of Medicine, St. Lucia, USA.
⁵ Clinical Research, Texas Center for Drug Development, Texas, USA.
⁶ Internal Medicine, Dr. Somervell Memorial CSI Medical College and Hospital, Kerala, IND.
⁷ Pediatrics, Ayub Teaching Hospital, Abbottabad, PAK.
⁸ Internal Medicine, University of Health Sciences (UHS), Lahore, PAK.
⁹ Internal Medicine, Jersey City Medical Center, Jersey City, USA.
¹⁰ Internal Medicine, Hayatabad Medical Complex, Peshawar, PAK.
¹¹ Internal Medicine, Khyber Medical College Peshawar, Hayatabad Medical Complex, Peshawar, PAK.

Abstract

Introduction Erectile dysfunction (ED) is a prevalent medical condition that affects millions of men globally. A number of pharmacological and complementary options are used in the management of ED, including Coenzyme Q10 (CoQ10). Oxidative stress has been linked to the progression of ED, and Co Q10 protects against oxidative damages and improves erectile function as well as the activity of antioxidant enzymes. This study aimed to determine the efficacy of CoQ10 in the treatment of erectile dysfunction in hypertensive males. Method An open-labeled parallel arm interventional study was conducted in the cardiology unit of Hayatabad Medical Complex Hospital, Peshawar, Pakistan, from March 2020 to March 2021. Hypertensive male patients (n = 230) were randomly allocated to either receiving 200-gram CoQ10 daily along with their current antihypertensive therapy (n=104) or anti-hypertensive treatment only (n=105). The patient's erectile function was assessed at baseline and three months using the International Index of Erectile Function Test (IIEF-5) during the study period. Result Of the total 230, 209 (90.87%) patients were included in the final analysis. There were no significant differences in demographics, history of illness, co-morbid conditions, and current medication of both groups. After three months, 21 (20.1%) participants scored more than 17 in the IIEF-5 and no longer had ED. Overall, no significant difference was found in the mean IIEF-5 score between the study group and control group (14.41 ± 4.49 Vs. 15.61 ± 4.82; p=0.06). However, in subgroup analysis, significant improvement in the study group was seen in participants with mild ED (p=0.03). Conclusion With the demonstration of its efficacy in hypertensive patients with mild ED, co-enzyme Q10 supplementation can be proposed as a potential candidate in patients with long-term hypertension and can play a role in erectile dysfunction.

Keywords: alpha blocker; b-blocker; coenzyme q10; erectile dysfunction; hypertension.